Leitlinien für Diagnostik und Therapie in der Neurologie: Prophylaxe der Migräne mit monoklonalen Antikörpern gegen CGRP oder den CGRP-Rezeptor

Hans Christoph Diener; Stefanie Förderreuther; Charly Gaul; Florian Giese; Till Hamann; Dagny Holle-Lee; Tim P. Jürgens; Katharina Kamm; Torsten Kraya; Christian Lampl; Arne May; Uwe Reuter; Armin Scheffler; Peer Tfelt-Hansen

Leitlinien für Diagnostik und Therapie in der Neurologie: Prophylaxe der Migräne mit monoklonalen Antikörpern gegen CGRP oder den CGRP-Rezeptor

Translated title of the contribution: Guidelines for diagnosis and therapy in neurology: Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor. Supplement to the guideline 030/057 for the therapy of migraine attacks and prevention of migraine

Hans Christoph Diener^*, Stefanie Förderreuther, Charly Gaul, Florian Giese, Till Hamann, Dagny Holle-Lee, Tim P. Jürgens, Katharina Kamm, Torsten Kraya, Christian Lampl, Arne May, Uwe Reuter, Armin Scheffler, Peer Tfelt-Hansen

^*Corresponding author for this work

Department of Neurology

Abstract

Monoclonal antibodies against the calcitonin gene-related peptide (CGRP) receptor (erenumab) or against CGRP (eptinezumab, fremanezumab, galcanezumab) are new substances for the preventive treatment of migraine. They represent an extension of the therapeutic options which already exist in migraine prevention. In registration studies, the efficacy and good tolerability of these specific substances have been demonstrated in patients with episodic and chronic migraine. The following treatment recommendation presents a summary of the pivotal studies. Recommendations are given for the targeted selection of patients as well as for the evaluation of therapeutic success and the duration of treatment. Finally, possible restrictions in the use of this new substance group are discussed.

Translated title of the contribution	Guidelines for diagnosis and therapy in neurology: Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor. Supplement to the guideline 030/057 for the therapy of migraine attacks and prevention of migraine
Original language	German
Journal	Arzneimitteltherapie
Volume	38
Issue number	3
Pages (from-to)	69-92
Number of pages	24
ISSN	0723-6913
Publication status	Published - 1 Jan 2020

Access to Document

https://www.arzneimitteltherapie.de/heftarchiv/2020/03/leitlinien-fuer-diagnostik-und-therapie-in-der-neurologie-prophylaxe-der-migraene-mit-monoklonalen-antikoerpern-gegen-cgrp-oder-den-cgrp-rezeptor-ergaenzung-der-leitlinie-030-057-therapie-der-migraeneattacke-und-prophylaxe-der-migraene-1.html

Fingerprint

Dive into the research topics of 'Guidelines for diagnosis and therapy in neurology: Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor. Supplement to the guideline 030/057 for the therapy of migraine attacks and prevention of migraine'. Together they form a unique fingerprint.

Cite this

Diener, H. C., Förderreuther, S., Gaul, C., Giese, F., Hamann, T., Holle-Lee, D., Jürgens, T. P., Kamm, K., Kraya, T., Lampl, C., May, A., Reuter, U., Scheffler, A., & Tfelt-Hansen, P. (2020). Leitlinien für Diagnostik und Therapie in der Neurologie: Prophylaxe der Migräne mit monoklonalen Antikörpern gegen CGRP oder den CGRP-Rezeptor. Arzneimitteltherapie, 38(3), 69-92. https://www.arzneimitteltherapie.de/heftarchiv/2020/03/leitlinien-fuer-diagnostik-und-therapie-in-der-neurologie-prophylaxe-der-migraene-mit-monoklonalen-antikoerpern-gegen-cgrp-oder-den-cgrp-rezeptor-ergaenzung-der-leitlinie-030-057-therapie-der-migraeneattacke-und-prophylaxe-der-migraene-1.html

Leitlinien für Diagnostik und Therapie in der Neurologie: Prophylaxe der Migräne mit monoklonalen Antikörpern gegen CGRP oder den CGRP-Rezeptor. / Diener, Hans Christoph; Förderreuther, Stefanie; Gaul, Charly et al.
In: Arzneimitteltherapie, Vol. 38, No. 3, 01.01.2020, p. 69-92.

Research output: Contribution to journal › Journal article › Research › peer-review

Diener, HC, Förderreuther, S, Gaul, C, Giese, F, Hamann, T, Holle-Lee, D, Jürgens, TP, Kamm, K, Kraya, T, Lampl, C, May, A, Reuter, U, Scheffler, A & Tfelt-Hansen, P 2020, 'Leitlinien für Diagnostik und Therapie in der Neurologie: Prophylaxe der Migräne mit monoklonalen Antikörpern gegen CGRP oder den CGRP-Rezeptor', Arzneimitteltherapie, vol. 38, no. 3, pp. 69-92. <https://www.arzneimitteltherapie.de/heftarchiv/2020/03/leitlinien-fuer-diagnostik-und-therapie-in-der-neurologie-prophylaxe-der-migraene-mit-monoklonalen-antikoerpern-gegen-cgrp-oder-den-cgrp-rezeptor-ergaenzung-der-leitlinie-030-057-therapie-der-migraeneattacke-und-prophylaxe-der-migraene-1.html>

@article{0d06a5f4f2d642108ef8f6fd5d3fb2c0,

title = "Leitlinien f{\"u}r Diagnostik und Therapie in der Neurologie: Prophylaxe der Migr{\"a}ne mit monoklonalen Antik{\"o}rpern gegen CGRP oder den CGRP-Rezeptor",

abstract = "Monoclonal antibodies against the calcitonin gene-related peptide (CGRP) receptor (erenumab) or against CGRP (eptinezumab, fremanezumab, galcanezumab) are new substances for the preventive treatment of migraine. They represent an extension of the therapeutic options which already exist in migraine prevention. In registration studies, the efficacy and good tolerability of these specific substances have been demonstrated in patients with episodic and chronic migraine. The following treatment recommendation presents a summary of the pivotal studies. Recommendations are given for the targeted selection of patients as well as for the evaluation of therapeutic success and the duration of treatment. Finally, possible restrictions in the use of this new substance group are discussed.",

author = "Diener, \{Hans Christoph\} and Stefanie F{\"o}rderreuther and Charly Gaul and Florian Giese and Till Hamann and Dagny Holle-Lee and J{\"u}rgens, \{Tim P.\} and Katharina Kamm and Torsten Kraya and Christian Lampl and Arne May and Uwe Reuter and Armin Scheffler and Peer Tfelt-Hansen",

year = "2020",

month = jan,

day = "1",

language = "Tysk",

volume = "38",

pages = "69--92",

journal = "Arzneimitteltherapie",

issn = "0723-6913",

publisher = "Wissenschaftliche Verlagsgesellschaft mbH",

number = "3",

}

TY - JOUR

T1 - Leitlinien für Diagnostik und Therapie in der Neurologie

T2 - Prophylaxe der Migräne mit monoklonalen Antikörpern gegen CGRP oder den CGRP-Rezeptor

AU - Diener, Hans Christoph

AU - Förderreuther, Stefanie

AU - Gaul, Charly

AU - Giese, Florian

AU - Hamann, Till

AU - Holle-Lee, Dagny

AU - Jürgens, Tim P.

AU - Kamm, Katharina

AU - Kraya, Torsten

AU - Lampl, Christian

AU - May, Arne

AU - Reuter, Uwe

AU - Scheffler, Armin

AU - Tfelt-Hansen, Peer

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Monoclonal antibodies against the calcitonin gene-related peptide (CGRP) receptor (erenumab) or against CGRP (eptinezumab, fremanezumab, galcanezumab) are new substances for the preventive treatment of migraine. They represent an extension of the therapeutic options which already exist in migraine prevention. In registration studies, the efficacy and good tolerability of these specific substances have been demonstrated in patients with episodic and chronic migraine. The following treatment recommendation presents a summary of the pivotal studies. Recommendations are given for the targeted selection of patients as well as for the evaluation of therapeutic success and the duration of treatment. Finally, possible restrictions in the use of this new substance group are discussed.

AB - Monoclonal antibodies against the calcitonin gene-related peptide (CGRP) receptor (erenumab) or against CGRP (eptinezumab, fremanezumab, galcanezumab) are new substances for the preventive treatment of migraine. They represent an extension of the therapeutic options which already exist in migraine prevention. In registration studies, the efficacy and good tolerability of these specific substances have been demonstrated in patients with episodic and chronic migraine. The following treatment recommendation presents a summary of the pivotal studies. Recommendations are given for the targeted selection of patients as well as for the evaluation of therapeutic success and the duration of treatment. Finally, possible restrictions in the use of this new substance group are discussed.

UR - https://www.scopus.com/pages/publications/85084572120

M3 - Tidsskriftartikel

AN - SCOPUS:85084572120

SN - 0723-6913

VL - 38

SP - 69

EP - 92

JO - Arzneimitteltherapie

JF - Arzneimitteltherapie

IS - 3

ER -

Leitlinien für Diagnostik und Therapie in der Neurologie: Prophylaxe der Migräne mit monoklonalen Antikörpern gegen CGRP oder den CGRP-Rezeptor

Abstract

Access to Document

Other files and links

Fingerprint

Cite this